Dosing completed in the vulvodynia study

Initiator Pharma has announced final dosing of the last planned patient in its Phase IIa vulvodynia study of pudafensine, with the programme therefore on track to release top-line data in February 2027. In our view, the read-out represents an important near-term event for the equity story and could improve investor sentiment, following the stock’s weak performance YTD.

What’s new? The company has announced that the last planned patient has been enrolled and dosed in its Phase IIa vulvodynia study of pudafensine, completing recruitment of all 24 planned participants. The study’s main objectives are to evaluate the efficacy and safety of a single dose. Using a randomised, double-blind, crossover design, each patient receives a single oral dose of pudafensine and a placebo during separate treatment periods, separated by washout intervals. This allows for a direct within-patient comparison of treatment effects.

What does it mean? The announcement provides an updated timeline for expected topline data in February 2027, compared with the previous guidance of year-end. Although this is a Phase IIa study without a parallel control arm, we believe the crossover design should still provide valuable efficacy evidence if the results are positive. In that scenario, positive data could meaningfully de-risk the programme and enhance its attractiveness to potential partners.

What do we do? We consider the news positive. We estimate that pudafensine could have peak sales potential in vulvodynia of USD1.6bn if approved, with our current risk assessment implying a likelihood of approval of 15%.